B.R.A.I.N. Biotechnology Research And Information Network AG: Global beverage company has joined DOLCE
Global beverage company has joined DOLCE
Zwingenberg, Potsdam (Germany) and Lestrem (France), 12 July, 2017: The bioeconomy company BRAIN AG (ISIN DE0005203947 / WKN 520394), the natural product specialist AnalytiCon Discovery GmbH and Roquette, a global leader in specialty food ingredients from plant-based raw materials, announced today that a globally operating US-based beverage company entered the strategic DOLCE program as a new member. The DOLCE program was started in August 2016 and offers consumer product goods companies ("CPGCs") a platform providing expert know-how to develop and produce natural sweetening solutions in order to achieve sugar- and calorie reduction in diverse food and beverage categories.
Such CPGCs have the opportunity to become DOLCE members in defined food and beverage fields. The advantage for those members is that they will be informed about developments at an early stage, are allowed to work pre-approval with the development candidates and can acquire licenses for selected natural sweet solutions. In return, the CPGCs provide several payment streams such as upfront, milestone, success and licence payments.
The three DOLCE research partners together have been in discussions with many of the global Fortune 500 CPGCs representing the largest food and beverage brands. Already in November 2016, two food categories "morning foods" and "snacks" have joined the strategic DOLCE program.
The globally operating US-based beverage company, as a new member, will have an exclusive access in the field "non-alcoholic beverages" as well as a non-exclusive access in the fields "dairy drinks" and "ginger ales and tonics". The interest of this new CPGC member is to integrate innovative and all natural DOLCE sweet solutions into their end products to address the need for sugar reduction in the global beverage market. Further details of the partnership are not disclosed.
Since the start of the DOLCE programme, the consortium partners have received great interest from many globally operating CPGCs. The categories that have already joined the DOLCE programme are proof of the strong potential of this co-operation which, of course, remains open for further participants.
According to Transparency Market Research, the global non-alcoholic beverages market was estimated at a total of USD 1.4 trillion in 2013. The global carbonated beverages market, as one part of this, was estimated over USD 340 billion in 2014 (source: Grand View Research Inc.). Along with trends towards natural and healthy ingredients, high caloric sugar and chemical sugar substitutes have the potential to be more and more replaced by natural high intensity sweeteners or sweet taste enhancers across product categories like bakery and cereal, beverage, and confection.
BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en. IR Contact: BžRžAžIžN Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany Tel.: +49-6251-9331-16 Fax: +49-6251-9331-11 E-Mail: firstname.lastname@example.org www.brain-biotech.deDisclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
12.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg
Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: email@example.com Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service